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Among 16541 3-year survivors of childhood cancer in Britain, 39 soft tissue sarcomas (STSs) occurred and 1.1 sarcomas were
expected, yielding a standardised incidence ratio (SIR) of 16.1. When retinoblastomas were excluded from the cohort, the SIR for
STSs was 15.9, and the cumulative risk of developing a soft tissue tumour after childhood cancer within 20 years of 3-year survival was
0.23%. In the case–control study, there was a significant excess of STSs in those patients exposed to both radiotherapy (RT) and
chemotherapy, which was five times that observed among those not exposed (P¼0.02). On the basis of individual radiation
dosimetry, there was evidence of a strong dose–response effect with a significant increase in the risk of STS with increasing dose of
RT (Po0.001). This effect remained significant in a multivariate model. The adjusted risk in patients exposed to RT doses of over
3000cGy was over 50 times the risk in the unexposed. There was evidence of a dose–response effect with exposure to alkylating
agents, the risk increasing substantially with increasing cumulative dose (P¼0.05). This effect remained after adjusting for the effect of
radiation exposure.
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Survival after childhood cancer has greatly improved over the last
three decades and most recent figures indicate that about 75% of
children diagnosed with cancer are likely to survive at least 5 years
(Toms, 2004). Thus a growing number of survivors, estimated at 1
in every 1000 young adults (Hawkins and Stevens, 1996), are at risk
of various adverse late effects of both the cancer and its treatment.
The well-recognised increased risk of a second malignant
neoplasm (SMN) (Meadows et al, 1985) may represent the greatest
challenge to long-term survival (Robison and Mertens, 1993).
Further study of their causes, which include both exposure to
chemotherapy (CT), radiotherapy (RT) and genetic predisposition
(Kony et al, 1997), requires follow-up of large numbers of
survivors with a wide spectrum of treatments.
Soft tissue sarcoma (STS) represents an important risk of SMN
following childhood cancer, particularly heritable retinoblastoma
(Draper et al, 1986; Hawkins et al, 1987; Westermeier et al, 1998;
Menu-Branthomme et al, 2004). The one published case–control
study of STS following childhood cancer demonstrated an
independent association with exposure to RT and CT with
procarbazine (Menu-Branthomme et al, 2004).
We here examined the incidence of STS in a population-based
cohort of 3-year survivors of childhood cancer in Britain, and
explored their aetiological factors in a much larger case–control
analysis than previously reported. For present purposes, STS
occurring as an SMN will be referred to simply as STS.
MATERIALS AND METHODS
Cohort study
A cohort of 3-year survivors of childhood cancer was selected from
the National Register of Childhood Tumours (NRCT), a popula-
tion-based national register covering the whole of Great Britain,
which is maintained by the Childhood Cancer Research Group
(CCRG), at the University of Oxford. The register is notified of all
cancers occurring in individuals below 15 years through the
national cancer registration system in Britain, which was
established in 1962. In addition, a complementary series of 3-year
survivors of childhood cancer diagnosed before this date was
constructed from case lists obtained from individual hospitals and
cancer registries.
Soft tissue sarcomas were ascertained by several methods. First,
cohort members were ‘flagged’ at the National Health Service
Central Registers (NHSCR), a system that provides automatic
notification of the registration of death or further cancer in these
individuals (Hawkins and Swerdlow, 1982). At the time of
finalising the cohort, virtually all cancer registrations for 1990
and earlier years had been fully processed at NHSCR and notified
to researchers. Second, a series of postal questionnaires enquiring
about any STS were sent to the family doctors of the survivors over
the period 1982 to 1990, providing an independent source of
ascertainment for 82% of the person-years of follow-up. Finally,
the CCRG receives all death certificates, which mention neoplasia
in patients aged less than 20 years in Britain. These are routinely
checked through family doctor and hospital notes to identify
multiple primary tumours. The cohort consisted of all malignant
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subsequently survived at least 3 years. Soft tissue sarcomas were
included if they were diagnosed before the study end point of 31
December 1990, after which the completeness of ascertainment is
uncertain.
Pathological criteria
For each individual in the cohort, the first primary tumour was
classified according to the International Classification of Diseases
for Oncology (ICDO) (World Health Organization, 1976), and
subsequently categorised into special diagnostic groups (Birch and
Marsden, 1987). Soft tissue sarcomas were classified according to
ICDO (World Health Organization, 1976). Soft tissue sarcomas
were also classified by ICD-9 (World Health Organization, 1979) as
general population incidence figures are available for this tumour
classification.
Statistical methods
Statistical tests and confidence intervals were based on the
assumption that the observed numbers of cancers followed a
Poisson distribution with mean equal to the expected number of
cases. Person-years at risk were accumulated from entry into the
study (at 3-year survivorship) until exit (defined as diagnosis of
STS, death, emigration or study end point of 31 December 1990,
whichever was first). The standardised incidence ratio (SIR) is the
ratio of the observed to the expected number of cancers within the
cohort. Expected numbers were estimated by accumulating
person-years at risk within specific categories defined by 5-year
age groups, sex and single calendar year, and then multiplying
these by the general population incidence rate of malignant disease
within the corresponding category (Breslow and Day, 1987; Office
of National Statistics, 1999). The additive excess risk is the
difference between the observed and the expected number of STSs
divided by the person-years at risk and multiplied by 1000, and is a
measure of the excess number of cancers per 1000 survivors per
year (Breslow and Day, 1987).
Case–control study
Fifty-three cases of STS were identified as described above, of
which 39 were diagnosed before 31 December 1990 and nested
within the cohort study. The remaining 14 cases included here
were diagnosed during 1991–1996.
For each case, we attempted to select four matched controls
from the NRCT on the following criteria:
(1) Age at first cancer (within 1 year of the age at diagnosis of the
case);
(2) Sex;
(3) Histological diagnosis of the first cancer, classification codes
I–XI (Birch and Marsden, 1987). Retinoblastomas were also
matched as to whether heritable or non-heritable, the former
including either bilateral disease or a family history; the
remainder were defined as non-heritable;
(4) Period of first cancer diagnosis – within the same 5-year
period: 1925–1929, 1930–1934, 1935–1939, etc;
(5) The interval survived free of STS from first cancer diagnosis to
exit for the control needed to be greater than or equal to the
interval from first cancer to SSTS in the matched case.
The exit date for each case was the date of STS, and for each
control the date at diagnosis of the first cancer plus the interval
from first cancer to second cancer in the matched case.
All cases of STS in the case–control study underwent
independent pathological review; representative sections from
both primary and secondary cancers were obtained wherever
possible and the diagnosis confirmed by a paediatric pathologist.
For each control, wherever possible, the original pathology report
of the first cancer was obtained from the patient’s medical records.
Medical information from cancer registry data, hospital and
occasionally GP records for the cases covered CT and RT for the
first cancer and for any recurrences up until STS diagnosis,
together with family and personal history of genetic conditions or
cancer.
Radiation dosimetry
For those cases and controls receiving RT, the original prescription
sheets, planning diagrams and treatment details were obtained.
These were anonymised, then electronically scanned onto CDs and
sent to the Department of Radiation Physics, MD Anderson Cancer
Center in Houston, for detailed radiation dosimetry. For sarcomas
within areas treated for the first tumour, standard radiation
therapy data were used to estimate dose. For sarcomas outside
such areas, doses were based on radiation measurements in water
phantoms, applied to a three-dimensional mathematically de-
scribed anthropomorphic phantom that simulated patients of
various ages. Contributions from collimator scatter, head leakage
and scatter within the patient were included in the final
calculations (Stovall et al, 2006). Dose categories (to cases and
controls) to the relevant soft tissue sites were as follows: 0.1–
49cGy, 50–999cGy, 1000–2999cGy and 3000cGy and above.
Chemotherapy
Chemotherapy details for each individual course or cycle of
treatment were coded, including dates of the start and end of each
course along with the name of each drug, the dose and route of
administration, and whether given alone or with other cytotoxic
therapy. Cytotoxic agents were grouped by mode of action, the
commonest being alkylating agents, vinca alkaloids, anti-tumour
antibiotics, antimetabolites and epipodophyllotoxins. The cumu-
lative dose of alkylating agents received was divided into four
categories of increasing exposure: 0.0–5999mg, 6000–11999mg,
and X12000mg.
Numbers of cases and controls were compared using standard
conditional logistic regression methods (Breslow and Day, 1980)
using EGRET epidemiological software (1999). All tests of
significance are two-tailed unless otherwise stated.
RESULTS
Cohort study
The cohort comprised 16541 3-year survivors of childhood cancer
diagnosed 1926–1987, and followed-up for a mean of 10 years
(median: 7 years 7 months), with a mean age at diagnosis of 6 years
8 months (median: 5 years 10 months). A total of 39 STSs met the
ICDO definition, and 17 of these were classified by ICD-9 as 171
compared to 1.1 expected from population incidence rates, giving
an SIR of 16.1 (95% CI 9.4, 25.8). When retinoblastomas were
excluded, the SIR for STS was 15.9 (95% CI 8.9, 26.2). The first
cancer diagnoses in cases of STS were Wilms’ (4), brain and CNS
(4), heritable retinoblastoma (2), Hodgkins’ (2) and 1 each of
neuroblastoma, acute lymphoblastic leukaemia, bone cancer, STS
and renal cell carcinoma.
The highest risks of STS followed primary Wilms’ tumour and
heritable retinoblastoma with SIRs of 45.9 (95% CI 12.5, 117.4) and
41.3 (95% CI 5.0, 149), respectively. There was no evidence of
significant heterogeneity or trend in the SIRs when analysed by
duration of follow-up from the first cancer, age at diagnosis of the
first cancer and period of diagnosis. Similar analyses revealed
evidence of heterogeneity in SIRs by treatment for the primary
cancer, of borderline statistical significance (Table 1). No STSs
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greatest risk (SIR¼34.5) was after exposure to both RT and CT.
The cumulative risk of STS after childhood cancer (excluding
retinoblastoma) within 20 years of 3-year survival was 0.23%
(s.e.¼0.07%) by the ICD-8 and -9 and 0.44% (s.e.¼0.1%) using
the ICDO.
Case–control study
In all, 53 cases of STS were included, of which 39 were nested
within the cohort study (25 cases male and 28 female). The mean
interval between diagnoses of first cancer and STS was 16 years
and 4 months (mean age at diagnosis of STS, 23 years). All original
diagnoses were histologically confirmed, 43 cases (81%) being
subject to central pathological review, 1 (2%) underwent central
pathological review as part of a clinical trial and the remaining 9
(17%) had insufficient tissue available for histological verification
of the original diagnosis. Thirty cases had 4 controls, 15 had 3, 6
had 2 and 2 had 1, a total of 179 controls.
Treatment
Eight controls with missing information regarding RT or CT were
designated ‘no record’. Using those exposed to neither RT nor CT
as the reference or unexposed category (i.e. relative risk (RR)¼1),
all treatment categories (RT, CT and both) showed excess risks,
significantly so with exposure to both RT and CT (P¼0.02), with
STS risk almost five times higher than in the unexposed group, a
broad indication of treatment-related risk.
Most individuals were treated with RT either alone or with CT
(79% cases and 71% controls). There was an excess risk of STS in
the exposed group (RR¼1.6; 95% CI 0.7, 3.7) compared with the
unexposed. Details of STS risks are shown in Table 2, including a
significant dose– response relationship with increasing cumulative
dose of radiation; the RR in the highest exposure category
(3000cGy and over) was 38 times that seen in the reference group
(Po0.001), with evidence of heterogeneity (Po0.001) and linear
trend (Po0.001) in risks across the different exposure categories.
When the RR was adjusted for the effect of exposure to alkylating
agents, by fitting a factor with four exposure levels, there remained
a significant dose–response relationship, the risk in the highest
exposure category being over 50 times that in the unexposed
group.
Chemotherapy, received by 43% of cases and 34% of controls,
was associated with a significantly elevated risk of STS (RR¼3.1;
95% CI 1.1, 8.8). The results for alkylating agents are presented in
Table 3. Univariate analysis showed a dose–response relationship
(P¼0.05) with risk highest in those exposed to over 12000mg
alkylating agent (RR¼4.73; P¼0.043). The relative risk across the
dose categories demonstrated evidence of a linear trend (P¼0.05).
After adjustment for radiation dose (five levels), there remained a
significant linear trend across the dose categories (P¼0.05). No
dose–response relationship was found with vinca alkaloids, and
other categories of drugs contained insufficient numbers for
analysis.
The 14 STS cases diagnosed after the study end point may not be
representative of all cases if ascertainment was incomplete, thereby
introducing potential bias of the risk assessment with RT or CT.
An analysis excluding STS cases diagnosed after 1990 found excess
risks of STS following all anti-cancer treatments, with a significant
excess for patients receiving both RT and CT (P¼0.03). In the
highest RT exposure group (3000cGy and over), risk was 37-fold
(95% CI 3.3, 418) than in the unexposed group. However, the
numbers were too small for the CT model to converge.
Table 1 Observed and expected numbers of sarcomas and SIRs for developing second soft tissue sarcomas after childhood cancer (excluding
retinoblastoma) by treatment for the primary cancer
Treatment received for the first cancer
Number entering
risk interval Observed Expected SIR 95% CI for SIR
No RT or CT 2190 0 0.19
CT only 1433 1 0.06 16.9 0.4, 94.1
RT only 3498 6 0.34 17.6 6.5, 38.3
Both RT and CT 5620 8 0.23 34.5 14.9, 68.0
Statistical test for heterogeneity in SIRs P¼0.08
CI¼confidence interval; CT¼chemotherapy; RT¼radiotherapy; SIRs¼standardised incidence ratios.
Table 2 RRs of developing a second soft tissue sarcoma in relation to cumulative dose of radiation
Number of patients (median
dose in cGy)
RR (95% CIs) RR (95% CI)
Dose of radiation (cGy) to site of second STS Cases Controls Unadjusted P-value
Adjusted for alkylating
agent exposure P-value
No record 2 10
0 11 55 1.0 1.0
1–49 9 (12) 46 (11) 1.02 (0.36, 2.88) 0.97 1.28 (0.35, 4.63) 0.711
50–999 8 (180) 42 (180) 2.4 (0.59, 9.58) 0.22 3.73 (0.78, 17.7) 0.098
1000–2999 13 (1810) 16 (1605) 21.8 (3.3, 143.8) 0.0014 37.08 (4.45, 309.3) o0.001
X3000 10 (3765) 10 (4000) 38.5 (5.19, 285.2) o0.001 51.35 (5.97, 441.5) o0.001
Likelihood ratio test for evidence of heterogeneity in
RR over the five different exposure categories
Po0.001 Po0.001
Likelihood ratio test for evidence of linear trend across
the five different exposure categories
Po0.001 Po0.001
CI¼confidence intervals; RRs¼relative risks; STS¼soft tissue sarcoma. Adjusted RRs and P-values were derived by simultaneously fitting a factor for alkylating agent exposure
with four levels of exposure.
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The cohort analysis gives an overall SIR of developing an STS of
16.1, similar to that after excluding retinoblastomas as first cancer
(SIR¼15.9). Soft tissue sarcoma accounted for 5.8% of all SMNs
and represented the second highest risk (SIR¼16.1) after secondary
bone cancer (SIR¼41.1) (Jenkinson et al, 2004). The greatest STS
risk followed Wilms’ tumour (SIR¼45.9) and heritable retinoblas-
toma (SIR¼41.3), based on four and two cases respectively. Despite
the high risk of STS compared with that in the general population,
this equates to a reassuringly low absolute risk of 0.44%.
Whereas a strong association between heritable retinoblastoma
and STS is well established (Draper et al, 1986; Eng et al, 1993;
Wong et al, 1997), that with Wilms’ tumour is less well known. A
large cohort of Wilms’ tumour survivors (5278) treated during
1969–1991 developed a number of both solid tumours (Breslow
et al, 1995) and haematological second malignancies (Shearer et al,
2001). Of the 34 secondary solid tumours, 22 (65%) occurred
within previously irradiated tissue and 13 (60%) of these were
bone sarcomas or STS; STS risk was associated with both RT and
CT (doxorubicin) (Breslow et al, 1995).
The overall cumulative risk of STS (based on ICD-8 and -9)
within 20 years of a childhood cancer was 0.23%, lower than that
(0.44%) based on ICDO, which included an additional 22 cases.
The discrepancy between the 17 STS cases diagnosed by ICD-9 (in
the cohort analysis) and the 39 cases classified by ICDO (in the
case–control study) highlights an issue in classifying childhood
cancer by site-based classification codes, as generally used in
international comparisons. Thus ICD-8 and -9 coding misses STS
of liver, kidney, breast, lung and bladder. For such reasons, a
classification for childhood cancer was introduced which was
based upon both morphology and site (Birch and Marsden, 1987),
and this scheme was used to identify the cases included in the
case–control study.
This, the largest case–control study of STS among survivors of
childhood cancer, finds a highly significant dose–response
relationship with RT, the risk increasing with increasing cumula-
tive dose to soft tissue (trend Po0.001). This relationship persisted
after adjusting for the effect of exposure to alkylating agents in a
multivariate conditional logistic regression model. The adjusted
risk to those exposed to 3000cGy or more was over 50-fold (95%
CI 6.0, 441) the risk in tissue unexposed to RT. A case–control
study of 25 STS found that an increased risk was related to the
square of the RTdose to the site at which the STS developed
(Menu-Branthomme et al, 2004).
As the risks of secondary sarcomas of bone and soft tissue have
often been considered together, it seems reasonable to compare the
case–control findings reported here with those from previous
studies of bone sarcomas after childhood cancer. In a nested case–
control study of 64 cases of bone cancer, a strong dose–response
relationship was found with radiation exposure (Tucker et al,
1987), while a similar pattern of risk was reported from a case–
control study of 59 cases among 3-year survivors of childhood
cancer (Hawkins et al, 1996). The fall in relative risk at the highest
doses of RT may have been due to chance and reflect the wide
confidence intervals, but it may also result from the ‘cell-killing’
phenomenon reported by a number of other workers (Boice et al,
1987). In a smaller case–control study of second bone cancers that
also demonstrated an increasing risk with increasing cumulative
dose of both RT and CT (mainly alkylating agents), the risk of
second bone cancers was found to be a linear function of the local
RT dose, with an excess relative risk of 1.8 per gray (Le Vu et al,
1998). The similarities between these studies of bone cancer and
the present study of STS support our conclusion that risk increases
with increasing cumulative dose of radiation.
A dose–response relationship was also found with alkylating
agent CT. After adjusting for RT in a multivariate model, the risk
to patients receiving over 12gm
 2 of alkylating agents was five
times (95% CI 1.1, 30.6) that in the unexposed. Procarbazine, an
alkylating agent, was also an independent risk factor for STS
(Menu-Branthomme et al, 2004). Conclusions from case–control
studies investigating second bone sarcomas have been very similar
including a dose–response relationship (Tucker et al, 1987;
Hawkins et al, 1996). Some evidence has been reported of
anthracyclines as a potential STS risk factor (Neglia et al, 2001).
Chemotherapy has also been implicated in excess risks of SMN
after Hodgkin’s disease (Kaldor et al, 1987; Tucker et al, 1988;
Hancock et al, 1993; Cellai et al, 2001). The investigation of
individual cytotoxic agents will require much larger numbers of
exposed individuals and probably international collaboration.
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Table 3 RR of developing a second soft tissue sarcoma in relation to cumulative exposure to alkylating agents
Number of patients (median
dose in mg)
RR (95% CI) RR (95% CI)
Cumulative dose of alkylating agents in
mgm
 2 Cases Controls Unadjusted P-value
Adjusted for
radiotherapy exposure P-value
No record 6 16
0 36 128 1.0 1.0
0–5999 2 (2413) 11 (3795) 0.85 (0.14, 5.12) 0.856 0.39 (0.04, 3.54) 0.403
6000–11999 4 (9452) 15 (7839) 1.72 (0.29, 10.49) 0.554 2.33 (0.2, 27.32) 0.499
12000 and above 5 (15895) 9 (13988) 4.73 (1.05, 21.36) 0.043 5.72 (1.07, 30.64) 0.042
Likelihood ratio test for evidence of heterogeneity
in RR over the four different exposure categories
P¼0.215 P¼0.126
Likelihood ratio test for evidence of linear trend
across the four different exposure categories
P¼0.05 P¼0.05
CI¼confidence intervals; RR¼relative risk. Adjusted RRs and P-values were derived by simultaneously fitting a factor for radiation exposure with five levels of exposure.
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